KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
==================================================================================================================================

* Pier Francesco Ferrucci
* Anna Maria Di Giacomo
* Michele Del Vecchio
* Victoria Atkinson
* Henrik Schmidt
* Jacob Schachter
* Paola Queirolo
* Georgina V Long
* Rosalie Stephens
* Inge Marie Svane
* Michal Lotem
* Mahmoud Abu-Amna
* Eduard Gasal
* Razi Ghori
* Scott J Diede
* Elizabeth S Croydon
* Antoni Ribas
* Paolo Antonio Ascierto